A
B
C
D
E
100

Timing of antibiotic therapy in suspected sepsis


(1) 


Within first hour

100

Systemic sclerosis variant associated with PAH 


(2)


Limited cutaneous systemic sclerosis

100

Treatment for cyanide poisoning 


(3)

Hydroxocobalamin

100


Ventilatory treatment of acute hypercapnic respiratory failure attributable to OHS 

(4)

BPAP

100

Most sensitive test for small pleural effusions 

(5)

Ultrasonography

200

Treatment for severe radiation pneumonitis 


(6)

 

Glucocorticoids

200

Treatment for snoring and mild OSA 



(7)


Weight loss

200

Timing of initiation of enteral nutrition in ICU


(8)

24-48 hours after admission

200

Glucocorticoid treatment for moderate to severe COPD exacerbation


(9)

Oral prednisone 40 mg for 5 days

200

 Treatment for shock refractory to fluids and vasopressors 



(10)

 

 

Hydrocortisone

300

Bedside tool to evaluate ICU-acquired weakness 


(11)


Medical Research Council muscle scale

300

Role of sputum culture in COPD exacerbation 


(12)

None

300

Empiric antibiotic class for bronchiectasis exacerbation 


(13) 


Fluoroquinolone

300

COPD indications for supplemental oxygen 

PO2 ___ mm Hg, O2 saturation ___%


(14)

PO2 ≤55 mm Hg, O2 saturation ≤88%

300

Possible complication in air travel for patients with asthma or COPD 



(15)

Pneumothorax

400

Recommended vaccinations for all patients with chronic lung disease 


(16) 

PPSV23 and annual influenza 

400

Primary treatment for ARDS 


(17) 

Mechanical ventilation with PEEP

400


Nonventilatory oxygen support for acute hypoxemic respiratory failure 


(18)

 


High-flow nasal cannula

400

ARDS tidal volume 



(19)

4-8 mL/kg predicted body weight

400

Diagnostic tests for allergic bronchopulmonary aspergillosis 

(20) 


Aspergillus-specific IgE and IgG; Aspergillus antigen skin test 

500

 

Pleural fluid pH and glucose level characteristic of complicated parapneumonic effusion 

(21)

 

pH <7.2, glucose <60 mg/d

500
  • PDE-4 inhibitor to reduce severe COPD exacerbations and chronic bronchitis symptoms 


(22)



Roflumilast

500

Prevention of extubation failure in high-risk patients


(23)

Early NPPV

500


 Pulmonary infections suggestive of bronchiectasis



(24)

Pseudomonas aeruginosa, Aspergillus, non-TB mycobacteria

500

Contraindications to NPPV 

(Atleast 3)



(25)


Altered mental status, increased secretions, vomiting, inability to protect airway

M
e
n
u